Ignite Creation Date:
2025-12-24 @ 10:45 PM
Ignite Modification Date:
2026-01-01 @ 5:00 PM
Study NCT ID:
NCT05826535
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2023-03-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'}, {'id': 'D008224', 'term': 'Lymphoma, Follicular'}, {'id': 'D016393', 'term': 'Lymphoma, B-Cell'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C024352', 'term': 'fludarabine'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}], 'ancestors': [{'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 270}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-05-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2031-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-23', 'studyFirstSubmitDate': '2023-03-24', 'studyFirstSubmitQcDate': '2023-04-12', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-04-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase 1: Evaluate the safety and tolerability of a single dose of LYL314 administered as a single agent', 'timeFrame': 'Baseline to Month 24', 'description': 'Incidence of dose-limiting toxicities (DLTs) and other treatment-emergent adverse events (TEAEs)'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314, as measured by ORR', 'timeFrame': 'Baseline to Month 24', 'description': 'ORR based on Independent Review Committee (IRC) assessment per Lugano criteria'}], 'secondaryOutcomes': [{'measure': 'Phase 1: Evaluate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'Overall response rate (ORR), Complete response rate (CRR), duration of response (DOR), duration of complete response (DOCR), progression free survival (PFS) based on Investigator assessment until a pivotal trial (Phase 2) portion is initiated at which time all scans will be reviewed by an IRC assessment (Cohort 1) per Lugano criteria'}, {'measure': 'Phase 1: Evaluate the feasibility of treatment with LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'Proportion of enrolled participants who receive the target dose of LYL314'}, {'measure': 'Phase 1: Evaluate the pharmacokinetics of LYL314 when administered as a single agent', 'timeFrame': 'Baseline to Month 24', 'description': 'Maximum concentration (Cmax), area under the curve from time 0 to Day 28 (AUC0-28) and persistence of LYL314'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'ORR based on Investigator assessment per Lugano criteria'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'DOR based on IRC assessment and investigator assessment per Lugano criteria'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'Time to response (TTR) based on IRC assessment and investigator assessment per Lugano criteria'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 24', 'description': 'PFS based on IRC assessment and investigator assessment per Lugano criteria'}, {'measure': 'Phase 2: Estimate the efficacy of LYL314', 'timeFrame': 'Baseline to Month 72', 'description': 'Overall Survival (OS)'}, {'measure': 'Phase 2: Evaluate the safety and tolerability of a single dose of LYL314 administered as a single agent', 'timeFrame': 'Baseline to Month 24', 'description': 'Incidence and severity of TEAEs'}, {'measure': 'Phase 2: Evaluate the pharmacokinetics of LYL314 when administered as a single agent', 'timeFrame': 'Baseline to Month 24', 'description': 'Maximum concentration (Cmax), area under the curve from time 0 to Day 28 (AUC0-28) and persistence of LYL314'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CAR T-cell', 'Non-Hodgkin Lymphoma', 'CD19/20', 'CD19', 'CD20', 'NHL', 'Diffuse Large B-cell lymphoma', 'DLBCL', 'Transformed follicular lymphoma', 'TFL', 'Primary mediastinal B-cell lymphoma', 'PMBCL', 'High-grade B-cell lymphoma', 'HGBL', 'follicular lymphoma Grade 3B', 'large cell follicular lymphoma', 'Aggressive B-cell NHL', 'Refractory Aggressive B-Cell Lymphoma', 'Refractory B-Cell Non-Hodgkin Lymphoma', 'Lymphoma, Non-Hodgkin', 'Lymphoma', 'Lymphoma, Large B-Cell, Diffuse', 'Cyclophosphamide', 'Fludarabine', 'Lymphoma, Follicular', 'Lymphoma, B-cell', 'Immunosuppressive Agents', 'Immunologic Factors', 'Disease Attributes', 'Immune System Diseases', 'Recurrence', 'PiNACLE'], 'conditions': ['Relapsed Non-Hodgkin Lymphoma', 'Refractory Non-Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma', 'Large B-cell Lymphoma']}, 'descriptionModule': {'briefSummary': 'This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.', 'detailedDescription': 'This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.\n\nFive cohorts of participants will be enrolled:\n\nCohort 1: Participants who have not received a prior CAR T-cell product (CAR T naïve) and have received at least two or more prior lines of treatment (third-line or later).\n\nCohort 2: Participants who have received a prior CAR T-cell product (CAR T experienced) and have received at least two or more prior lines of treatment including one CAR T-cell therapy.\n\nCohort 3: Participants with refractory disease or relapse within one year of first-line therapy (second-line).\n\nCohort 4: Participants who have received prior T-cell engager (TCE) therapy and have received at least two or more prior lines of treatment including one TCE therapy.\n\nCohort 5: Participants receiving first-line treatment for high-risk large B-cell lymphoma who remain with disease on positron emission tomography scanning (PET-positive) after 2 to 3 cycles of standard-of-care chemoimmunotherapy (high-risk first-line).\n\nUp to approximately 150 participants (across all cohorts) will be enrolled in the dose finding Phase 1 part of the study.\n\nThe Phase 2 pivotal study (PiNACLE) will expand enrollment of Cohort 1 to approximately 120 participants to further evaluate the safety and efficacy of LYL314.\n\nLYL314 treatment consists of a single administration of CAR transduced autologous T-cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days.\n\nIndividual participants will remain in the active post-treatment follow-up (PTFU) period for approximately 2 years. Participants will continue in long-term follow-up (LTFU) for 15 years from LYL314 treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Age 18 years or older at time of informed consent\n2. Willing and able to provide written informed consent\n3. Histologically confirmed aggressive NHL, including the following types defined by the World Health Organization (WHO 2017):\n\n * DLBCL\n * DLBCL arising from follicular lymphoma (transformed FL, tFL)\n * Primary mediastinal (thymic) large B-cell lymphoma (PMBCL)\n * High-grade large B-cell lymphoma with or without MYC and BCL2 and/or BCL6 rearrangement (HGBL)\n * Grade 3B follicular lymphoma/Large cell follicular lymphoma (FL3B)\n4. Received at least two prior lines of therapy for Cohorts 1, 2, and 4 and one prior line of therapy for Cohort 3. Prior therapy must have included:\n\n * Anti-CD20 monoclonal antibody, and\n * An anthracycline containing chemotherapy regimen\n * Participants with tFL must have received at least one of their prior lines of therapy after transformation to DLBCL\n\n 4b. Cohort 5 (High-risk first-line) participants must have high-risk large B-cell lymphoma\n5. Relapsed or refractory disease, defined by the following:\n\n * Disease progression after last regimen (including salvage therapy after autologous stem cell transplantation \\[ASCT\\]). In participants who have only received front-line therapy, progression should be ≤ 12 months of first-line therapy (applicable for Cohort 3)\n * In patients who received one line of therapy, refractory disease is defined as failure to achieve at least a PR after at least 4 cycles of therapy (applicable for Cohort 3)\n * In patients who received two or more lines of therapy (Cohorts 1, 2, and 4), refractory disease is defined as failure to achieve a CR to last line of therapy (including CAR T and/or salvage therapy).\n6. At least 1 measurable lesion (per Lugano classification). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or ECOG 0 to 2 (Cohort 5)\n8. Absolute neutrophil count (ANC) ≥ 1000/uL\n9. Platelet count ≥ 50,000/uL\n10. Absolute lymphocyte count (ALC) ≥ 200/uL\n\nOther protocol-defined criteria apply.\n\nExclusion Criteria:\n\n1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 3 years. Participants who have received therapy for a prior malignancy within the prior 3 years, e.g., in the adjuvant setting, are not excluded\n2. Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or by lumbar puncture. Participants with prior evidence of brain metastasis treated at least 8 weeks prior to enrollment will not be excluded for participation if CNS disease is deemed stable at the time of study enrollment\n3. History of cardiac lymphoma involvement or Epstein-Barr virus (EBV)+ lymphoma\n4. Ongoing or impending oncologic emergency (e.g., tumor mass effect, tumor lysis syndrome, known vascular invasion)\n5. Received the following therapies in the specified time frame prior to enrollment/leukapheresis\n\n 1. Any systemic therapy within 2 weeks\n 2. Any systemic inhibitory/stimulatory immune checkpoint molecule therapy within 3 half-lives prior to enrollment (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists)\n 3. Fludarabine within 12 weeks\n 4. Alemtuzumab, bendamustine or antithymocyte globuline (ATG) within 6 months\n 5. Any T cell engager/bispecific antibody therapy such as CD20/CD3 or CD19/CD3 bispecific antibodies within 4 weeks\n 6. Any experimental therapy within 4 weeks or 5 half-lives (whichever is shorter)\n6. Received radiation therapy within 3 weeks prior to enrollment/leukapheresis\n7. Experiencing non-hematologic toxicities due to prior therapy. Exceptions include: stable and recovered to grade ≤ 1 or non-clinically significant toxicities such as (1) alopecia, (2) toxicities where Grade 2 is solely defined by participant receiving hormone replacement therapy for endocrinopathies resulting from previous checkpoint inhibitor therapy, (3) Grade 2 lymphopenia, and (4) hearing loss or Grade 2 neuropathy associated with prior treatment with taxanes or platinating agents\n8. History of allogeneic stem cell or solid organ transplantation\n9. Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment/leukapheresis\n10. History of prior genetically modified cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). For all other CAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor is required\n11. Primary immunodeficiency\n12. History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years. Participants who have other autoimmune condition(s) considered to be associated with underlying malignancy may be enrolled in the study after discussion with and approval of the Medical Monitor.\n\nOther protocol-defined criteria apply."}, 'identificationModule': {'nctId': 'NCT05826535', 'briefTitle': 'Study of LYL314 in Aggressive Large B-Cell Lymphoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Lyell Immunopharma, Inc.'}, 'officialTitle': 'A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma', 'orgStudyIdInfo': {'id': 'LYL314-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Phase 1 CAR T naïve (Cohort 1)', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1 CAR T experienced (Cohort 2)', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1 Refractory disease or relapse within one year of first-line therapy (Cohort 3)', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1 Received T-cell engager (TCE) therapy (Cohort 4)', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 1 Receiving first-line treatment for high-risk large B-cell lymphoma (Cohort 5)', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}, {'type': 'EXPERIMENTAL', 'label': 'Phase 2 CAR T naïve (Cohort 1)', 'description': 'Single dose determined during Phase 1.', 'interventionNames': ['Drug: LYL314', 'Drug: Fludarabine', 'Drug: Cyclophosphamide']}], 'interventions': [{'name': 'LYL314', 'type': 'DRUG', 'description': 'CAR T-cell therapy', 'armGroupLabels': ['Phase 1 CAR T experienced (Cohort 2)', 'Phase 1 CAR T naïve (Cohort 1)', 'Phase 1 Received T-cell engager (TCE) therapy (Cohort 4)', 'Phase 1 Receiving first-line treatment for high-risk large B-cell lymphoma (Cohort 5)', 'Phase 1 Refractory disease or relapse within one year of first-line therapy (Cohort 3)', 'Phase 2 CAR T naïve (Cohort 1)']}, {'name': 'Fludarabine', 'type': 'DRUG', 'description': 'Conditioning chemotherapy', 'armGroupLabels': ['Phase 1 CAR T experienced (Cohort 2)', 'Phase 1 CAR T naïve (Cohort 1)', 'Phase 1 Received T-cell engager (TCE) therapy (Cohort 4)', 'Phase 1 Receiving first-line treatment for high-risk large B-cell lymphoma (Cohort 5)', 'Phase 1 Refractory disease or relapse within one year of first-line therapy (Cohort 3)', 'Phase 2 CAR T naïve (Cohort 1)']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'description': 'Conditioning chemotherapy', 'armGroupLabels': ['Phase 1 CAR T experienced (Cohort 2)', 'Phase 1 CAR T naïve (Cohort 1)', 'Phase 1 Received T-cell engager (TCE) therapy (Cohort 4)', 'Phase 1 Receiving first-line treatment for high-risk large B-cell lymphoma (Cohort 5)', 'Phase 1 Refractory disease or relapse within one year of first-line therapy (Cohort 3)', 'Phase 2 CAR T naïve (Cohort 1)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92697', 'city': 'Irvine', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California-Irvine Medical Center', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'zip': '90048', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Cedars-Sinai Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California, Los Angeles (UCLA) Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92037', 'city': 'San Diego', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Scripps Clinic', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '80218', 'city': 'Denver', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Colorado Blood Cancer Institute', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '30912', 'city': 'Augusta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Augusta University Medical Center', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'zip': '46237', 'city': 'Indianapolis', 'state': 'Indiana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Indiana Blood and Marrow Transplantation', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Iowa', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Louisville Brown Cancer Center', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '71130', 'city': 'Shreveport', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Louisiana State University Health Sciences Center', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Corewell Health', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '68198', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Nebraska Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '87131', 'city': 'Albuquerque', 'state': 'New Mexico', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of New Mexico Comprehensive Cancer Center', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Montefiore Medical Center', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '45267', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Cincinnati (UC) Physicians Company, LLC', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '18103', 'city': 'Allentown', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Lehigh Valley Topper Cancer Center Institute', 'geoPoint': {'lat': 40.60843, 'lon': -75.49018}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Thomas Jefferson University', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Baylor University Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Texas Transplant Institute', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84112', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Huntsman Cancer Institute', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '84143', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Intermountain Healthcare', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '24502', 'city': 'Norfolk', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Virginia Oncology Associates', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Virginia Commonwealth University-Massey Cancer Center', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Medical College of Wisconsin', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}], 'centralContacts': [{'name': 'Lyell Immunopharma Inc.', 'role': 'CONTACT', 'email': 'clinicaltrials@lyell.com', 'phone': '888-707-7917'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Lyell Immunopharma, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}